Business Context and Reporting Period
This Form 8-K Current Report was filed by Proteon Therapeutics, Inc. (also referred to as Protara Therapeutics, Inc. in metadata) on October 16, 2015. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel appointments rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors from nine to ten, creating one vacancy.
- Director Appointment: Stuart A. Kingsley was appointed to fill the vacancy as a director in the second class, with a term expiring at the 2016 Annual Meeting of Stockholders.
- Independence Determination: The Board determined that Mr. Kingsley qualifies as "independent" under NASDAQ and SEC rules.
- Committee Appointment: Scott Canute, an existing director, was appointed to the Compensation Committee.
Compensation and Governance Details
In connection with his appointment, Mr. Kingsley will receive an annual cash retainer consistent with the Company's non-employee director compensation arrangements. Additionally, the Board granted Mr. Kingsley an option to purchase 13,333 shares of the Company's common stock. These shares will vest annually over three years from the grant date. The Company also plans to enter into a standard Indemnification Agreement with Mr. Kingsley.
Investor Verification Checklist
- Verify the total number of directors on the Board is now ten.
- Confirm the vesting schedule for the 13,333 stock options granted to Stuart A. Kingsley.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Check the Company's 2015 Proxy Statement for details on the standard annual cash retainer for non-employee directors.